All currently available inotropic agents act to increase Ca2+ for activation in both normal and failing myocardium (Hurst). The use of inotropic agents in the treatment of CHF is predicated on the finding that a major contributing factor in reducing ventricular performance results from depression of myocardial contractility and that this can be reversed, or at least improved, by inotropic drugs.